Document Detail


What is the evidence in humans that DNA methylation changes link events in utero and later life disease?
MedLine Citation:
PMID:  23374091     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Development in utero is now recognized as crucial to determining later life disease susceptibility. Whilst mechanisms are poorly understood, there has been considerable interest in the potential role of epigenetic processes in intra-uterine programming of disease. Epigenetic modifications include various mechanisms that influence chromatin structure and gene expression. Here, we review emerging data from human studies that altered DNA methylation links intra-uterine events with later life disease. Further research in this field is needed to determine whether altered DNA methylation in target tissues can be used as a biomarker for the early identification of and intervention in individuals most at risk of later life disease.
Authors:
Rebecca M Reynolds; Greta H Jacobsen; Amanda J Drake
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical endocrinology     Volume:  78     ISSN:  1365-2265     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-04-23     Completed Date:  2013-10-28     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  814-22     Citation Subset:  IM    
Copyright Information:
© 2013 John Wiley & Sons Ltd.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Biological Markers
Birth Weight
DNA Methylation*
Epigenesis, Genetic*
Female
Fetal Blood / metabolism
Fetal Development / genetics*
Genetic Predisposition to Disease / embryology*
Humans
Infant, Newborn
Obesity / etiology
Placenta / growth & development
Pregnancy
Prenatal Exposure Delayed Effects
Grant Support
ID/Acronym/Agency:
CZB/4/582//Chief Scientist Office; CZG/2/478//Chief Scientist Office; G0501904//Medical Research Council; SCD/09//Chief Scientist Office; //British Heart Foundation
Chemical
Reg. No./Substance:
0/Biological Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A time sequence analysis of the relationship between cardiovascular risk factors, vascular diseases ...
Next Document:  Scanning laser Doppler may predict disease progression of localised scleroderma in children and youn...